Telitacicept to prevent lupus flares
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have lupus that is currently mild or stable (low disease activity).
- You have been on a steady dose of your lupus medicines (like prednisone, hydroxychloroquine, or other immunosuppressants) for at least 3 months.
- You have not had cyclophosphamide or certain B-cell treatments (like Rituximab, Benlysta, or Telitacicept) in the last 6 months.
- You do not have serious kidney or liver problems, active infections, or a recent cancer history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
This trial compares two medications, telitacicept and belimumab, to see which is safer and more effective for treating lupus. It might help you if standard treatments haven't worked well for you.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
This trial tests a new medicine called telitacicept for people with connective tissue disease (like lupus or Sjögren's) whose platelet counts stay dangerously low despite standard treatments. It aims to raise platelet levels and reduce bleeding risk.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.